

CLAIMS

1. A polynucleotide encoding a polypeptide comprising the sequence  
FLDQVAFXV (Seq. ID No. 1), wherein X is any amino acid.

5

2. A polynucleotide encoding a polypeptide comprising the sequence  
FLFSWYAXV (Seq. ID No. 3), wherein X is any amino acid.

3. The complement of a polynucleotide of claim 1.

10

4. The complement of a polynucleotide of claim 2.

5. A gene delivery vehicle comprising a polynucleotide of any of  
claims 1 to 4.

15

6. The gene delivery vehicle of claim 5, wherein the vehicle is  
selected from the group consisting of a plasmid, a cosmid, a recombinant viral  
vector, and a liposome-containing vehicle.

20

7. The gene delivery vehicle of claim 5, wherein the recombinant viral  
vector is a recombinant DNA viral vector or a recombinant RNA viral vector.

8. A host cell comprising a polynucleotide of any of claims 1 to 4.

25

9. A method of recombinantly producing a polynucleotide,  
comprising growing the host cell of claim 8 and isolating the polynucleotide  
produced thereby.

10. A composition comprising a polynucleotide of any of claims 1 to 4,  
and a carrier.

30

11. The composition of claim 10, wherein the carrier is a solid support.

12. The composition of claim 10, wherein the carrier is a pharmaceutically acceptable carrier.

5

13. A polypeptide comprising the sequence FLDQVAFXV (Seq. ID No. 1), wherein X is any amino acid.

10

14. A polypeptide comprising the sequence FLFSWYAXV (Seq. ID No. 3), wherein X is any amino acid.

15. A polypeptide that is preferentially recognized by gp100 specific cytotoxic T lymphocytes which comprises the polypeptide of claim 13.

15

16. A polypeptide that is preferentially recognized by gp100 specific cytotoxic T lymphocytes which comprises the polypeptide of claim 14.

20

17. A method of recombinantly producing a polypeptide, comprising growing the host cell of claim 8 under conditions suitable for the transcription and translation of the polynucleotide and isolating the polypeptide produced thereby.

18. A composition comprising the polypeptide of claim 15 or 16 and a carrier.

25

19. The composition of claim 18, wherein the carrier is a solid support.

20. The composition of claim 19, wherein the carrier is a pharmaceutically acceptable carrier.

30

21. A host cell comprising the polypeptide of claim 15 or 16.

22. The host cell of claim 21, wherein the cell is an antigen presenting cell (APC) and the polypeptide is present on the surface of the cell.

23. The host cell of claim 22, wherein the APC is a dendritic cell.

24. A population of educated, antigen-specific immune effector cells produced by culturing naïve immune effector cells with antigen-presenting cells (APC) cells which express the polypeptide of claim 14 or claim 15 on the surface of the APCs.

25. The population of claim 24, wherein the antigen presenting cells (APCs) are dendritic cells.

26. The population of claim 24, wherein the immune effector cells are cytotoxic T lymphocytes (CTLs).

27. The population of claim 24, wherein immune effector cells are genetically modified.

28. The population of claim 24, wherein the antigen-presenting cells are genetically modified.

29. A composition comprising the population of any of claims 24 to 28, and a carrier.

30. The composition of claim 29, wherein the carrier is a pharmaceutically acceptable carrier.

31. A method of inducing an immune response in a subject, comprising administering to the subject an effective amount of the polypeptide of

claim 15 or 16, under the conditions that induce an immune response to the polypeptide.

5           32.     The method of claim 31, further comprising administering an effective amount of a cytokine to the subject.

          33.     The method of claim 31, further comprising administering an effective amount of a co-stimulatory molecule to the subject.

10           34.     A method of inducing an immune response to a melanoma antigen in a subject, comprising administering to the subject an effective amount of the antigen-presenting cell of claim 22 and under conditions that induce an immune response to the antigen.

15           35.     The method of claim 34, further comprising administering an effective amount of a cytokine to the subject.

          36.     The method of claim 34, further comprising administering an effective amount of a co-stimulatory molecule to the subject.

20           37.     The method of claim 34, wherein the antigen-presenting cell is genetically modified.

25           38.     The method of claim 37, further comprising genetically modifying the cell to express a cytokine.

          39.     The method of claim 37, further comprising genetically modifying the cell to express a co-stimulatory molecule.

40. A method of adoptive immunotherapy, comprising administering to a subject an effective amount of a population of educated, antigen-specific immune effector cells of any of claims 24 to 28.

5                    41.    A database comprising the the nucleotide sequence of any of the  
polynucleotides of claims 1 to 4.

Year	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	